Jongsook Kim Kemper
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jongsook Kim Kemper has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Ji Miao
Department of Molecular and Integrative Physiology, University of Illinois, Urbana-Champaign, Urbana, Illinois 61801, USA
10 shared publicationsSungsoon Fang
Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801
6 shared publicationsBhaskar Ponugoti
Department of Molecular and Integrative Physiology, University of Illinois, Urbana, Illinois 61801, USA
4 shared publicationsTimothy D. Veenstra
Laboratory of Proteomics and Analytical Technologies, Advanced Technology Program, SAIC—Frederick, Inc., National Cancer Institute—Frederick, Frederick, Maryland 21702
4 shared publicationsZhen Xiao
Laboratory of Proteomics and Analytical Technologies, Advanced Technology Program, SAIC—Frederick, Inc., National Cancer Institute—Frederick, Frederick, Maryland 21702
4 shared publicationsCheng-Ming Chiang
The ‖Departments of Biochemistry and Pharmacology, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas 75390
3 shared publications
Latest Publications
- 1 August 2011
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1812 (8) , 842-850
Regulation of FXR transcriptional activity in health and disease: Emerging roles of FXR cofactors and post-translational modifications
- 1 August 2011
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1812 (8) , 842-850
Regulation of FXR transcriptional activity in health and disease: Emerging roles of FXR cofactors and post-translational modifications
- Open Access
- 1 July 2011
- Published by The Endocrine Society in Molecular Endocrinology
- Vol. 25 (7) , 1159-1169
Ligand-Dependent Regulation of the Activity of the Orphan Nuclear Receptor, Small Heterodimer Partner (SHP), in the Repression of Bile Acid BiosyntheticCYP7A1andCYP8B1Genes
Small heterodimer partner (SHP) plays important roles in diverse biological processes by directly interacting with transcription factors and inhibiting their activities. SHP has been designated an orphan nuclear receptor, but whether its activity can be modulated by ligands has been a long-standing question. Recently, retinoid-related molecules, including 4-[3-(1-adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid (3Cl-AHPC), were shown to bind to SHP and enhance apoptosis. We have examined whether 3Cl-AHPC acts as an agonist and increases SHP activity in the repression of bile acid biosynthetic CYP7A1 and CYP8B1 genes and delineated the underlying mechanisms. Contrary to this expectation, micromolar concentrations of 3Cl-AHPC increased CYP7A1 expression but indirectly via p38 kinase signaling. Nanomolar concentrations, however, repressed CYP7A1 expression and decreased bile acid levels in HepG2 cells, and little repression was observed when SHP was down-regulated by small hairpin RNA. Mechanistic studies revealed that 3Cl-AHPC bound to SHP, increased the interaction of SHP with liver receptor homologue (LRH)-1, a hepatic activator for CYP7A1 and CYP8B1 genes, and with repressive cofactors, Brahma, mammalian Sin3a, and histone deacetylase-1, and, subsequently, increased the occupancy of SHP and these cofactors at the promoters. Mutation of Leu-100, predicted to contact 3Cl-AHPC within the SHP ligand binding pocket by molecular modeling, severely impaired the increased interaction with LRH-1, and repression of LRH-1 activity mediated by 3Cl-AHPC. 3Cl-AHPC repressed SHP metabolic target genes in a gene-specific manner in human primary hepatocytes and HepG2 cells. These data suggest that SHP may act as a ligand-regulated receptor in metabolic pathways. Modulation of SHP activity by synthetic ligands may be a useful therapeutic strategy.
- 1 July 2011
- Published by The Endocrine Society in Molecular Endocrinology
- Vol. 25 (7) , 1159-1169
Open AccessLigand-Dependent Regulation of the Activity of the Orphan Nuclear Receptor, Small Heterodimer Partner (SHP), in the Repression of Bile Acid BiosyntheticCYP7A1andCYP8B1Genes
Small heterodimer partner (SHP) plays important roles in diverse biological processes by directly interacting with transcription factors and inhibiting their activities. SHP has been designated an orphan nuclear receptor, but whether its activity can be modulated by ligands has been a long-standing question. Recently, retinoid-related molecules, including 4-[3-(1-adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid (3Cl-AHPC), were shown to bind to SHP and enhance apoptosis. We have examined whether 3Cl-AHPC acts as an agonist and increases SHP activity in the repression of bile acid biosynthetic CYP7A1 and CYP8B1 genes and delineated the underlying mechanisms. Contrary to this expectation, micromolar concentrations of 3Cl-AHPC increased CYP7A1 expression but indirectly via p38 kinase signaling. Nanomolar concentrations, however, repressed CYP7A1 expression and decreased bile acid levels in HepG2 cells, and little repression was observed when SHP was down-regulated by small hairpin RNA. Mechanistic studies revealed that 3Cl-AHPC bound to SHP, increased the interaction of SHP with liver receptor homologue (LRH)-1, a hepatic activator for CYP7A1 and CYP8B1 genes, and with repressive cofactors, Brahma, mammalian Sin3a, and histone deacetylase-1, and, subsequently, increased the occupancy of SHP and these cofactors at the promoters. Mutation of Leu-100, predicted to contact 3Cl-AHPC within the SHP ligand binding pocket by molecular modeling, severely impaired the increased interaction with LRH-1, and repression of LRH-1 activity mediated by 3Cl-AHPC. 3Cl-AHPC repressed SHP metabolic target genes in a gene-specific manner in human primary hepatocytes and HepG2 cells. These data suggest that SHP may act as a ligand-regulated receptor in metabolic pathways. Modulation of SHP activity by synthetic ligands may be a useful therapeutic strategy.
- 1 June 2011
- Published by The Endocrine Society
- p. P1-769
Ligand-Dependent Regulation of the Activity of the Orphan Nuclear Receptor, Small Heterodimer Partner (SHP), in the Repression of the Hepatic Bile Acid Biosynthetic CYP7A1 and CYP8B1 Genes
Small Heterodimer Partner (SHP) plays important roles in diverse biological processes including metabolism, tumorigenesis, and reproduction by directly interacting with transcription factors and inhibiting their activities. SHP has been designated as an orphan nuclear receptor but whether its activity can be modulated by ligands has been a long-standing question. Recently, retinoid-related molecules including 4-[3-(1-adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid (3Cl-AHPC) were shown to bind to SHP and enhance apoptosis. We have examined whether 3Cl-AHPC acts as an agonist and increases SHP activity in the regulation of bile acid biosynthetic CYP7A1 and CYP8B1 genes and delineated the underlying mechanisms. Nanomolar concentrations of 3Cl-AHPC repressed CYP7A1 expression in HepG2 cells but little repression was observed when SHP was downregulated by shRNA. Surprisingly, micromolar concentrations of 3Cl-AHPC increased CYP7A1 expression via p38 kinase signaling. Mechanistic studies revealed that 3Cl-AHPC bound to SHP, increased interaction of SHP with LRH-1, a hepatic activator for CYP7A1 and CYP8B1 genes, and with repressive cofactors, Brm, mSin3A, and HDAC1, and, subsequently, increased the promoter occupancy of SHP and these cofactors. Mutation of Leu-100, predicted to contact 3Cl-AHPC within the SHP ligand binding pocket by molecular modeling, severely impaired increased interaction with LRH-1 and repression of LRH-1 activity mediated by 3Cl-AHPC. Treatment with 3Cl-AHPC repressed SHP target genes in metabolic pathways in a gene-specific manner in human heptocytes and HepG2 cells. These data suggest that SHP can act as a ligand-regulated nuclear receptor in metabolic pathways. Modulation of SHP activity by synthetic ligands may be a useful therapeutic strategy. Nothing to Disclose: S-EC, JM, SMS, LY, JKK
- 1 June 2011
- Published by The Endocrine Society
- p. P1-769
Ligand-Dependent Regulation of the Activity of the Orphan Nuclear Receptor, Small Heterodimer Partner (SHP), in the Repression of the Hepatic Bile Acid Biosynthetic CYP7A1 and CYP8B1 Genes
Small Heterodimer Partner (SHP) plays important roles in diverse biological processes including metabolism, tumorigenesis, and reproduction by directly interacting with transcription factors and inhibiting their activities. SHP has been designated as an orphan nuclear receptor but whether its activity can be modulated by ligands has been a long-standing question. Recently, retinoid-related molecules including 4-[3-(1-adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid (3Cl-AHPC) were shown to bind to SHP and enhance apoptosis. We have examined whether 3Cl-AHPC acts as an agonist and increases SHP activity in the regulation of bile acid biosynthetic CYP7A1 and CYP8B1 genes and delineated the underlying mechanisms. Nanomolar concentrations of 3Cl-AHPC repressed CYP7A1 expression in HepG2 cells but little repression was observed when SHP was downregulated by shRNA. Surprisingly, micromolar concentrations of 3Cl-AHPC increased CYP7A1 expression via p38 kinase signaling. Mechanistic studies revealed that 3Cl-AHPC bound to SHP, increased interaction of SHP with LRH-1, a hepatic activator for CYP7A1 and CYP8B1 genes, and with repressive cofactors, Brm, mSin3A, and HDAC1, and, subsequently, increased the promoter occupancy of SHP and these cofactors. Mutation of Leu-100, predicted to contact 3Cl-AHPC within the SHP ligand binding pocket by molecular modeling, severely impaired increased interaction with LRH-1 and repression of LRH-1 activity mediated by 3Cl-AHPC. Treatment with 3Cl-AHPC repressed SHP target genes in metabolic pathways in a gene-specific manner in human heptocytes and HepG2 cells. These data suggest that SHP can act as a ligand-regulated nuclear receptor in metabolic pathways. Modulation of SHP activity by synthetic ligands may be a useful therapeutic strategy. Nothing to Disclose: S-EC, JM, SMS, LY, JKK
- Open Access
- 1 April 2011
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 31 (7) , 1540-1550
Arginine Methylation by PRMT5 at a Naturally Occurring Mutation Site Is Critical for Liver Metabolic Regulation by Small Heterodimer Partner
Small Heterodimer Partner (SHP) inhibits numerous transcription factors that are involved in diverse biological processes, including lipid and glucose metabolism. In response to increased hepatic bile acids, SHP gene expression is induced and the SHP protein is stabilized. We now show that the activity of SHP is also increased by posttranslational methylation at Arg-57 by protein arginine methyltransferase 5 (PRMT5). Adenovirus-mediated hepatic depletion of PRMT5 decreased SHP methylation and reversed the suppression of metabolic genes by SHP. Mutation of Arg-57 decreased SHP interaction with its known cofactors, Brm, mSin3A, and histone deacetylase 1 (HDAC1), but not with G9a, and decreased their recruitment to SHP target genes in mice. Hepatic overexpression of SHP inhibited metabolic target genes, decreased bile acid and hepatic triglyceride levels, and increased glucose tolerance. In contrast, mutation of Arg-57 selectively reversed the inhibition of SHP target genes and metabolic outcomes. The importance of Arg-57 methylation for the repression activity of SHP provides a molecular basis for the observation that a natural mutation of Arg-57 in humans is associated with the metabolic syndrome. Targeting posttranslational modifications of SHP may be an effective therapeutic strategy by controlling selected groups of genes to treat SHP-related human diseases, such as metabolic syndrome, cancer, and infertility.
- 1 April 2011
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 31 (7) , 1540-1550
Open AccessArginine Methylation by PRMT5 at a Naturally Occurring Mutation Site Is Critical for Liver Metabolic Regulation by Small Heterodimer Partner
Small Heterodimer Partner (SHP) inhibits numerous transcription factors that are involved in diverse biological processes, including lipid and glucose metabolism. In response to increased hepatic bile acids, SHP gene expression is induced and the SHP protein is stabilized. We now show that the activity of SHP is also increased by posttranslational methylation at Arg-57 by protein arginine methyltransferase 5 (PRMT5). Adenovirus-mediated hepatic depletion of PRMT5 decreased SHP methylation and reversed the suppression of metabolic genes by SHP. Mutation of Arg-57 decreased SHP interaction with its known cofactors, Brm, mSin3A, and histone deacetylase 1 (HDAC1), but not with G9a, and decreased their recruitment to SHP target genes in mice. Hepatic overexpression of SHP inhibited metabolic target genes, decreased bile acid and hepatic triglyceride levels, and increased glucose tolerance. In contrast, mutation of Arg-57 selectively reversed the inhibition of SHP target genes and metabolic outcomes. The importance of Arg-57 methylation for the repression activity of SHP provides a molecular basis for the observation that a natural mutation of Arg-57 in humans is associated with the metabolic syndrome. Targeting posttranslational modifications of SHP may be an effective therapeutic strategy by controlling selected groups of genes to treat SHP-related human diseases, such as metabolic syndrome, cancer, and infertility.
- Open Access
- 1 October 2010
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 285 (44) , 33959-33970
SIRT1 Deacetylates and Inhibits SREBP-1C Activity in Regulation of Hepatic Lipid Metabolism*
- 1 October 2010
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 285 (44) , 33959-33970
Open AccessSIRT1 Deacetylates and Inhibits SREBP-1C Activity in Regulation of Hepatic Lipid Metabolism*
- Open Access
- 5 August 2010
- Published by Impact Journals, LLC in Aging
- Vol. 2 (8) , 527-534
Controlling SIRT1 expression by microRNAs in health and metabolic disease
SIRT1 is a NAD+-dependent deacetylase implicated in longevity and diverse physiological processes. SIRT1, as a key mediator of beneficial effects of caloric restriction, regulates lipid and glucose metabolism by deacetylating metabolic regulators, as well as histones, in response to nutritional deprivation. Here we discuss how SIRT1 levels are regulated by microRNAs (miRs) which are emerging as important metabolic regulators; the recently identified nuclear receptor FXR/SHP cascade pathway that controls the expression of miR-34a and its target SIRT1; and a FXR/SIRT1 positive feedback regulatory loop, which is deregulated in metabolic disease states. The FXR/miR-34a pathway and other miRs controlling SIRT1 may be useful therapeutic targets for age-related diseases, including metabolic disorders.
- 5 August 2010
- Published by Impact Journals, LLC in Aging
- Vol. 2 (8) , 527-534
Open AccessControlling SIRT1 expression by microRNAs in health and metabolic disease
SIRT1 is a NAD+-dependent deacetylase implicated in longevity and diverse physiological processes. SIRT1, as a key mediator of beneficial effects of caloric restriction, regulates lipid and glucose metabolism by deacetylating metabolic regulators, as well as histones, in response to nutritional deprivation. Here we discuss how SIRT1 levels are regulated by microRNAs (miRs) which are emerging as important metabolic regulators; the recently identified nuclear receptor FXR/SHP cascade pathway that controls the expression of miR-34a and its target SIRT1; and a FXR/SIRT1 positive feedback regulatory loop, which is deregulated in metabolic disease states. The FXR/miR-34a pathway and other miRs controlling SIRT1 may be useful therapeutic targets for age-related diseases, including metabolic disorders.
- Open Access
- 1 April 2010
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 285 (17) , 12604-12611
A Pathway Involving Farnesoid X Receptor and Small Heterodimer Partner Positively Regulates Hepatic Sirtuin 1 Levels via MicroRNA-34a Inhibition
- 1 April 2010
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 285 (17) , 12604-12611
Open AccessA Pathway Involving Farnesoid X Receptor and Small Heterodimer Partner Positively Regulates Hepatic Sirtuin 1 Levels via MicroRNA-34a Inhibition
- 1 December 2009
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 29 (23) , 6170-6181
Functional Specificities of Brm and Brg-1 Swi/Snf ATPases in the Feedback Regulation of Hepatic Bile Acid Biosynthesis
Bile acid homeostasis is critical in maintaining health and is primarily regulated by the nuclear receptors farnesoid X receptor (FXR) and small heterodimer partner (SHP). Bile acid-activated FXR indirectly inhibits expression of cholesterol 7α hydroxylase (CYP7A1), a key enzyme in conversion of cholesterol to bile acids, by induction of SHP. We recently demonstrated that SHP inhibits CYP7A1 transcription by recruiting chromatin-modifying cofactors, including Brm-Swi/Snf. Swi/Snf complexes contain either Brm or Brg-1 ATPases, and whether these subunits have distinct functions remains unclear. We have examined the role of these subunits in regulation of bile acid metabolism under physiological conditions by FXR and SHP. Brg-1 interacted with FXR and enhanced FXR-mediated transactivation of SHP, whereas Brm interacted with SHP and enhanced SHP-mediated repression of CYP7A1 and, interestingly, auto-repression of SHP. Chromatin immunoprecipitation and remodeling studies revealed that after treatment with FXR agonists, Brg-1 was recruited to the SHP promoter, resulting in transcriptionally active accessible chromatin, whereas Brm was recruited to both CYP7A1 and SHP promoters, resulting in inactive inaccessible chromatin. Our studies demonstrate that Brm and Brg-1 have distinct functions in the regulation of two key genes, CYP7A1 and SHP, within a single physiological pathway, feedback inhibition of bile acid biosynthesis, by differentially targeting SHP and FXR.
- 1 December 2009
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 29 (23) , 6170-6181
Functional Specificities of Brm and Brg-1 Swi/Snf ATPases in the Feedback Regulation of Hepatic Bile Acid Biosynthesis
Bile acid homeostasis is critical in maintaining health and is primarily regulated by the nuclear receptors farnesoid X receptor (FXR) and small heterodimer partner (SHP). Bile acid-activated FXR indirectly inhibits expression of cholesterol 7α hydroxylase (CYP7A1), a key enzyme in conversion of cholesterol to bile acids, by induction of SHP. We recently demonstrated that SHP inhibits CYP7A1 transcription by recruiting chromatin-modifying cofactors, including Brm-Swi/Snf. Swi/Snf complexes contain either Brm or Brg-1 ATPases, and whether these subunits have distinct functions remains unclear. We have examined the role of these subunits in regulation of bile acid metabolism under physiological conditions by FXR and SHP. Brg-1 interacted with FXR and enhanced FXR-mediated transactivation of SHP, whereas Brm interacted with SHP and enhanced SHP-mediated repression of CYP7A1 and, interestingly, auto-repression of SHP. Chromatin immunoprecipitation and remodeling studies revealed that after treatment with FXR agonists, Brg-1 was recruited to the SHP promoter, resulting in transcriptionally active accessible chromatin, whereas Brm was recruited to both CYP7A1 and SHP promoters, resulting in inactive inaccessible chromatin. Our studies demonstrate that Brm and Brg-1 have distinct functions in the regulation of two key genes, CYP7A1 and SHP, within a single physiological pathway, feedback inhibition of bile acid biosynthesis, by differentially targeting SHP and FXR.
- 1 November 2009
- Published by Elsevier in Cell Metabolism
- Vol. 10 (5) , 392-404
FXR Acetylation Is Normally Dynamically Regulated by p300 and SIRT1 but Constitutively Elevated in Metabolic Disease States
- 1 November 2009
- Published by Elsevier in Cell Metabolism
- Vol. 10 (5) , 392-404
FXR Acetylation Is Normally Dynamically Regulated by p300 and SIRT1 but Constitutively Elevated in Metabolic Disease States
- 15 April 2009
- Published by Cold Spring Harbor Laboratory in Genes & Development
- Vol. 23 (8) , 986-996
Bile acid signaling pathways increase stability of Small Heterodimer Partner (SHP) by inhibiting ubiquitin–proteasomal degradation
Small Heterodimer Partner (SHP) inhibits activities of numerous transcription factors involved in diverse biological pathways. As an important metabolic regulator, SHP plays a key role in maintaining cholesterol and bile acid homeostasis by inhibiting cholesterol conversion to bile acids. While SHP gene induction by increased bile acids is well established, whether SHP activity is also modulated remains unknown. Here, we report surprising findings that SHP is a rapidly degraded protein via the ubiquitin–proteasomal pathway and that bile acids or bile acid-induced intestinal fibroblast growth factor 19 (FGF19) increases stability of hepatic SHP by inhibiting proteasomal degradation in an extracellular signal-regulated kinase (ERK)-dependent manner. SHP was ubiquitinated at Lys122 and Lys123, and mutation of these sites altered its stability and repression activity. Tandem mass spectrometry revealed that upon bile acid treatment, SHP was phosphorylated at Ser26, within an ERK motif in SHP, and mutation of this site dramatically abolished SHP stability. Surprisingly, SHP stability was abnormally elevated in ob/ob mice and diet-induced obese mice. These results demonstrate an important role for regulation of SHP stability in bile acid signaling in normal conditions, and that abnormal stabilization of SHP may be associated with metabolic disorders, including obesity and diabetes.
- 15 April 2009
- Published by Cold Spring Harbor Laboratory in Genes & Development
- Vol. 23 (8) , 986-996
Bile acid signaling pathways increase stability of Small Heterodimer Partner (SHP) by inhibiting ubiquitin–proteasomal degradation
Small Heterodimer Partner (SHP) inhibits activities of numerous transcription factors involved in diverse biological pathways. As an important metabolic regulator, SHP plays a key role in maintaining cholesterol and bile acid homeostasis by inhibiting cholesterol conversion to bile acids. While SHP gene induction by increased bile acids is well established, whether SHP activity is also modulated remains unknown. Here, we report surprising findings that SHP is a rapidly degraded protein via the ubiquitin–proteasomal pathway and that bile acids or bile acid-induced intestinal fibroblast growth factor 19 (FGF19) increases stability of hepatic SHP by inhibiting proteasomal degradation in an extracellular signal-regulated kinase (ERK)-dependent manner. SHP was ubiquitinated at Lys122 and Lys123, and mutation of these sites altered its stability and repression activity. Tandem mass spectrometry revealed that upon bile acid treatment, SHP was phosphorylated at Ser26, within an ERK motif in SHP, and mutation of this site dramatically abolished SHP stability. Surprisingly, SHP stability was abnormally elevated in ob/ob mice and diet-induced obese mice. These results demonstrate an important role for regulation of SHP stability in bile acid signaling in normal conditions, and that abnormal stabilization of SHP may be associated with metabolic disorders, including obesity and diabetes.